Affinia Therapeutics
43 Foundry Ave
Waltham
MA
United States
15 articles about Affinia Therapeutics
-
Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress
10/24/2023
Affinia Therapeutics today announced that the company will present preclinical data on its novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS) in a poster session at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, being held October 24-27, 2023, in Brussels, Belgium.
-
Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting
5/18/2023
Affinia Therapeutics today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS).
-
Affinia Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting
5/3/2023
Affinia Therapeutics today announced that new preclinical data will be presented in an oral and poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023 in Los Angeles, CA.
-
Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting
5/16/2022
Affinia Therapeutics today announced results from preclinical studies presented in an oral session at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.
-
Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors
3/8/2022
Affinia Therapeutics today announced the appointment of Diana M. Brainard, M.D. to its board of directors.
-
Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer
12/14/2021
Affinia Therapeutics today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer (CFO).
-
Affinia Therapeutics Appoints Carole Faig to Board of Directors
10/6/2021
Affinia Therapeutics today announced the appointment of Carole Faig to the Affinia Therapeutics Board of Directors.
-
Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group
9/8/2021
Affinia Therapeutics today announced the first two indications it will pursue with its next-generation gene therapies
-
Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy
7/20/2021
Affinia Therapeutics today announced a multi-year sponsored research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) focused on the central nervous system (CNS).
-
Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting
5/13/2021
Data shows multiple vectors with superiority to AAV9 in CNS, systemic approaches to target muscle while detargeting liver, and improvements in manufacturability
-
Money on the Move: April 29 – May 4
5/5/2021
April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world. -
Affinia Therapeutics Closes $110 Million Series B Financing
5/3/2021
Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus vectors and gene therapies for rare and non-rare diseases, announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management.
-
Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting
4/27/2021
Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting
-
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
2/17/2021
Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus vectors and gene therapies for rare and non-rare diseases, announced the completion of its leadership team.
-
Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors
6/8/2020
Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus vectors and gene therapies, announced the appointment of Elliott Sigal, M.D., Ph.D., to the company’s Board of Directors.